These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 3787181)

  • 21. Primary thrombocythemia.
    Jamshidi K; Ansari A; Windschitl HE; Swaim WR
    Geriatrics; 1973 Jan; 28(1):121-33. PubMed ID: 4539498
    [No Abstract]   [Full Text] [Related]  

  • 22. Leukemia and myelodysplasia effect of multiple cytotoxic therapy in essential thrombocythemia.
    Randi ML; Fabris F; Girolami A
    Leuk Lymphoma; 2000 Apr; 37(3-4):379-85. PubMed ID: 10752989
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of pipobroman in the treatment of polycythemia vera: long-term results in 163 patients.
    Passamonti F; Brusamolino E; Lazzarino M; Baraté C; Klersy C; Orlandi E; Canevari A; Castelli G; Merante S; Bernasconi C
    Haematologica; 2000 Oct; 85(10):1011-8. PubMed ID: 11025590
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pregnancy in a young woman affected by essential thrombocythemia: a case report.
    Ferrari A; Mazzucconi MG; Martinelli E; Giona F; Paesano R; Pachi A
    Haematologica; 1989; 74(1):115-6. PubMed ID: 2498176
    [No Abstract]   [Full Text] [Related]  

  • 25. [Anagrelide in the treatment of thrombocythemia essential (ET)].
    Mazur G; Wróbel T; Podolak-Dawidziak M; Kuliszkiewicz-Janus M; Potoczek S; Nosol J; Kuliczkowski K
    Pol Arch Med Wewn; 2004 Dec; 112(6):1445-50. PubMed ID: 15962609
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Treatment of essential thrombocythemia with anagrelide: a ten-year experience].
    Kornblihtt LI; Vassallu PS; Heller P; Molinas FC
    Medicina (B Aires); 2002; 62(3):231-6. PubMed ID: 12150005
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pegylated interferon for the treatment of high risk essential thrombocythemia: results of a phase II study.
    Langer C; Lengfelder E; Thiele J; Kvasnicka HM; Pahl HL; Beneke H; Schauer S; Gisslinger H; Griesshammer M
    Haematologica; 2005 Oct; 90(10):1333-8. PubMed ID: 16219569
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Essential thrombocythemia. Case reports and clinico-therapeutic considerations].
    Bottaro T; Cordì GC; Gaggero E; Motta A; Venzano C
    Minerva Med; 1990 Mar; 81(3):147-50. PubMed ID: 2320283
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980.
    Kiladjian JJ; Chevret S; Dosquet C; Chomienne C; Rain JD
    J Clin Oncol; 2011 Oct; 29(29):3907-13. PubMed ID: 21911721
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Leukemia and myelodysplasia in patients with essential thrombocythemia treated with cytotoxic agents.
    Randi ML; Fabris F; Girolami A
    Haematologica; 1999 Nov; 84(11):1049-50. PubMed ID: 10553169
    [No Abstract]   [Full Text] [Related]  

  • 31. Clinical course of essential thrombocythemia in 147 cases.
    Fenaux P; Simon M; Caulier MT; Lai JL; Goudemand J; Bauters F
    Cancer; 1990 Aug; 66(3):549-56. PubMed ID: 2364366
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Second malignancies in essential thrombocythemia (ET): a retrospective analysis of 331 patients with long-term follow-up from a single institution.
    Radaelli F; Onida F; Rossi FG; Zilioli VR; Colombi M; Usardi P; Calori R; Zanella A
    Hematology; 2008 Aug; 13(4):195-202. PubMed ID: 18796244
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Management of polycythaemia with pipobroman].
    Perreau-Boutet MC; Najman A; Stachowiak J; Parlier Y; Gorin NC; Duhamel G
    Nouv Presse Med; 1982 Sep; 11(34):2549-53. PubMed ID: 7133977
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Indications, procedure and results for the treatment of polycythaemia vera by bleeding, pipobroman and hydroxyurea.
    Boivin P
    Nouv Rev Fr Hematol (1978); 1993; 35(5):491-8. PubMed ID: 8295823
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Treatment of polycythemia. II.--Comparison of hydroxyurea with pipobroman in 294 patients less than 65 years of age].
    Najean Y; Rain JD; Lejeune F; Echard M; Fermand JP; Gruyer P; Brahimi S
    Ann Med Interne (Paris); 1998 Mar; 149(2):94-100. PubMed ID: 11490531
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term follow-up of 386 consecutive patients with essential thrombocythemia: safety of cytoreductive therapy.
    Palandri F; Catani L; Testoni N; Ottaviani E; Polverelli N; Fiacchini M; De Vivo A; Salmi F; Lucchesi A; Baccarani M; Vianelli N
    Am J Hematol; 2009 Apr; 84(4):215-20. PubMed ID: 19208420
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Therapy of essential thrombocythemia with thiotepa and chlorambucil.
    Case DC
    Blood; 1984 Jan; 63(1):51-4. PubMed ID: 6418235
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term outcomes of polycythemia vera patients treated with pipobroman as initial therapy.
    Kiladjian JJ; Gardin C; Renoux M; Bruno F; Bernard JF
    Hematol J; 2003; 4(3):198-207. PubMed ID: 12764352
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Alpha-interferon in polycythemia vera and essential thrombocythemia.
    Turri D; Mitra ME; Di Trapani R; Lipari MG; Perricone R; Cajozzo A
    Haematologica; 1991; 76(1):75-7. PubMed ID: 2055565
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase 3b, multicenter, open-label extension study of the long-term safety of anagrelide in Japanese adults with essential thrombocythemia.
    Kanakura Y; Shirasugi Y; Yamaguchi H; Koike M; Chou T; Okamoto S; Achenbach H; Wu J; Nakaseko C
    Int J Hematol; 2018 Nov; 108(5):491-498. PubMed ID: 30121892
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.